The company is focused on acquiring, developing, and commercializing novel treatments for B-cell malignancies and autoimmune diseases. TG Therapeutics is currently developing two therapies targeting hematologic malignancies: TG-1101, a glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes, and TGR-1202, an orally available PI3K delta inhibitor. Both therapies are in clinical development for patients with hematologic malignancies. TG Therapeutics also has a research pipeline including several investigational medicines, and has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).